iSERA Lifesciences Approves Share Swap to Acquire 100% Stake in iSERA Biological Limited

iSERA Lifesciences Approves Share Swap to Acquire 100% Stake in iSERA Biological Limited​

iSERA Lifesciences Limited, previously known as Covidh Technologies Limited, announced that its Board of Directors held a meeting on April 21, 2026, to approve several significant corporate actions, including the increase in authorized share capital, updating key foundational documents, and approving the acquisition of up to 100% of iSERA Biological Limited.

The Board approved the acquisition of shares from iSERA Biological Limited, which will ultimately make iSERA Biological Limited a Wholly Owned Subsidiary of iSERA Lifesciences Limited. This transaction involves a total consideration of Rs. 78,00,10,960/- (Rupees Seventy-Eight Crore Ten Thousand Nine Hundred and Sixty Only), which will be discharged entirely through a share swap mechanism.

Corporate Structure and Capital Changes​

During the board meeting, the directors considered and approved several fundamental changes to the Company’s corporate structure and governance framework:

• Increase in Authorized Share Capital: The Board approved increasing the authorized share capital from Rs. 11,00,00,000/- (Rupees Eleven Crore Only) to Rs. 25,00,00,000/- (Rupees Twenty-Five Crore Only). This increase involves the creation of 1,40,00,000 (One Crore Forty Lakh) additional Equity Shares of Rs. 10/- each.
• Updated Governing Documents: The Company also approved the adoption of a new set of Memorandum of Association (MOA) and a new set of Articles of Association (AOA). These updates are intended to align the Company's foundational documents with the Companies Act, 2013.
• Enhancement of Limits: The directors also approved the enhancement of the limits under Section 186 of the Companies Act, 2013, up to Rs. 1,000 Crore (Rupees One Thousand Crore Only).

Major Acquisition Details​

The Board approved the acquisition of equity shares representing up to 100% of the paid-up equity share capital of iSERA Biological Limited (CIN: U85300PN2016PLC165483). This acquisition is structured as a Related Party Transaction.

The transaction details and associated valuations were detailed as follows:


The directors confirmed that the issuance price of Rs. 48.20/- per equity share (of face value Rs. 10/- each) is not less than the floor price determined by the valuation reports.

Share Swap Mechanism​

The transaction mandates that the total consideration of Rs. 78,00,10,960/- shall be discharged entirely by the issuance and allotment of up to 1,61,82,800 fully paid-up equity shares of iSERA Lifesciences Limited, at a price of Rs. 48.20/- per share, on a preferential basis.

The swap ratio established is 1:1, meaning every one equity share of iSERA Biological Limited will be exchanged for one equity share of iSERA Lifesciences Limited.

Operational Approvals​

In addition to the primary acquisition, the Board also took approval for:

• Share Swap Agreement: The directors approved the Share Swap Agreement to be executed between the Company and the shareholders of iSERA Biological Limited.
• Preferential Issue: The Board approved the issuance of the shares to the existing shareholders of iSERA Biological Limited for consideration other than cash, establishing the preferential allotment on a share swap basis.
• Scrutinizer Appointment: CS Anuj Gupta was appointed as the Scrutinizer for the Postal Ballot / Remote E-Voting process.

The acquisition of the target entity, iSERA Biological Limited, is noted to be aligned with the Company's strategic vision to expand and consolidate its presence in the pharmaceutical and life sciences sector.

Stock Price Movement​

As of 10:14, Covidh Technologies Ltd is ticking up, currently trading at ₹71.29, marking a healthy gain of 1.99% for the day. However, the shares are showing zero volatility right now, remaining completely locked at ₹71.29 between their intraday high and low.